- In April 2023, Thermo Fisher Scientific announced the launch of a new line of enzyme immunoassay kits designed to improve diagnostic accuracy in detecting rare diseases. The kits utilize advanced biotechnological innovations to offer faster results and enhanced reliability in clinical testing. This development solidifies Thermo Fisher's leadership in the EIA reagents and devices market, reinforcing its commitment to advancing healthcare diagnostics in North America.
- In March 2023, Abbott Laboratories introduced a groundbreaking immunoassay platform, the ARCHITECT i1000SR, which offers a highly efficient and automated solution for clinical laboratories. This system significantly reduces turnaround times and increases the accuracy of test results for a variety of infectious diseases and chronic conditions. Abbott’s continuous innovation in EIA technologies is reshaping the diagnostic landscape in North America.
- In March 2023, PerkinElmer launched a new EIA diagnostic platform for early-stage cancer detection, featuring advanced biomarker detection technology designed to enhance screening accuracy and support early intervention in oncology.
